Risk of death by age and gender from CoVID-19 in Peru, March-May, 2020
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
SciScore for 10.1101/2020.06.14.20123315: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our study has at least two limitations. First, our estimates are probably overestimated, due to the effect of under reporting rates and ascertainment rates, as has been underscored in other studies [22, 24, 36]. But a recently enhanced testing capacity in Peru is expected to mitigate these effects, and an ongoing mass serological study …
SciScore for 10.1101/2020.06.14.20123315: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our study has at least two limitations. First, our estimates are probably overestimated, due to the effect of under reporting rates and ascertainment rates, as has been underscored in other studies [22, 24, 36]. But a recently enhanced testing capacity in Peru is expected to mitigate these effects, and an ongoing mass serological study will provide data to generate more accurate estimates of the death risk. Second, adjusted CFR, especially among seniors, has displayed fluctuations, highlighting the importance of focusing on sub-group analyses. Additional information such as line lists that include related risks including information on underlying diseases may help to identify subgroups with elevated risks.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
-
